FDA 向 503B 企业 RC Outsourcing 签发 8 条 483 观察项，涉无菌验证与同条件批次放行

眼内注射药也敢"无菌失败仍放行"？RC Outsourcing 8 条 483，背后还压着一封警告信

在俄亥俄州 Lowellville，有一家专门把 Avastin（贝伐珠单抗）分装成眼内注射针剂的企业——RC Outsourcing, LLC。针头扎进的是眼睛，最怕的就是污染。可 2026 年 9 月 3 日这份 483 显示：无菌失败批次被拒了，同一天、同一层流罩生产的其他批次却照常放行；而不溶性微粒标准，竟是 2024 年就被点过名的老问题。

互动 一支要打进眼睛的药，无菌失败调查不清、同条件批次还放行——你觉得这该不该触发召回？

一、背景：Avastin 分装这门生意，和一家身背警告信的 503B

这家公司是做什么的。RC Outsourcing, LLC，注册地址在俄亥俄州 Lowellville 102 E Water St，FDA 登记类别为"外包设施"（503B）。它的核心业务非常聚焦：把大包装的 Avastin（贝伐珠单抗）分装成 1.75mg/0.07mL 的单剂量注射器，供眼科医生做玻璃体腔注射，治疗湿性黄斑变性等眼底疾病。Avastin 本身是安进/罗氏的抗肿瘤药，"超适应症分装眼用"在美国眼科界极为普遍——一支 Avastin 分装剂只要几十美元，而同类眼内专用药要贵一个数量级。但代价是：这类分装全靠 503B 的无菌保障兜底，一旦污染，直接后果就是眼内炎（endophthalmitis），严重可致失明。2024–2025 年，全美多家 Avastin 分装商因眼内炎不良事件被 FDA 严厉处置，RC 就是其中一家。

签字的是谁。483 的接收人是业主本人——Raymond Robert Carlson。这在 483 的接收名单里很少见：FDA 把文书直接发给了所有权人，意味着检查层级已经到了"企业最高责任人"。签署人三名检查员，来自俄亥俄辛辛那提办公室（550 Main Street, Ste 4-930）：Kara J. Wright、Pushpa S. Jayasekara、Jeremy T. Dautrich，均为调查员，签发日期 2026 年 9 月 3 日。三人在 12 页纸上写满了视频时间码（烟雾研究的 T= 至 T= 段落）、批号矩阵和 SMT 细节——这是一支把"证据链做死"的检查组。

这不是第一次，甚至不是第三次。RC 的执法档案密得惊人：2024 年 9 月签发 483（观察项 6 的微粒标准问题在那份 483 里就已出现）；2024 年 11 月 4 日再签一份 483——本次观察项 6 明确写着"这是 2024 年 11 月 4 日 483 的重复观察项"；2025 年 8 月 28 日，检查员 Margaret M. Annes（也就是 Houston Rx 483 的签署人）又签出一份 483；该次检查直接引出2026 年 3 月 20 日的警告信 WL #722877，并伴随4 批贝伐珠单抗 1.75mg/0.07mL 因缺乏无菌保证发起的自愿召回。所有与 Avastin 眼内炎不良事件相关的批次，都是用这份有问题的微粒标准放行的。2026 年 8 月 24 日至 9 月 3 日（8/24–28、31，9/3，共 7 个工作日）的本次检查，就是在警告信和召回都未了结的背景下进行的。

这次检查怎么跑的。检查组的重心是"验证的真伪"：调阅了 2025 年 8 月与 2026 年 2 月两轮气流可视化（烟雾）研究的全部视频记录，逐段核对培养基灌装批记录、清洁记录、设备确认记录。8 条观察项里有大量"视频里没有拍到""记录里找不到"的表述——这份 483 拆穿的不是做错了什么，而是"证明做了"的那部分从来没做扎实。

二、逐条拆解：8 条，英文原文 + 中文还原

（以下每条中文表述均以 483 原文为据，并按上下文补全原文未言明之处以便阅读；(b)(4) 为 FDA 官方脱敏处，照原文保留；依上下文推测的内容以「（推断）」标出，非原文内容。）

观察项 1｜无菌/灭菌工艺验证不充分：烟雾研究没报告、介质填充不还原最差班次、无菌行为反复破防

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process. Specifically, A. Your firm conducted Airflow Visualization (AFV) studies (smoke studies) for ISO 5 Laminar Flow Hood (LFH (b)(4)) and Laminar Flow Hood (LFH (b)(4)) under both static and dynamic conditions in August 2025 and February 2026. No formal study reports or supporting documentation were available for review for either study. The records lacked the following critical study elements: the type of smoke sources, the stated study purpose, targeted test locations, and personnel activities performed during dynamic conditions, real-time observations, and conclusions. Although video recordings of the AFV studies were captured, they were not accompanied by written protocols, contemporaneous documentation, or summary reports sufficient to contextualize, interpret, or substantiate the visual findings. B. Discrepancies were identified in the AFV records (videos) for ISO 5 Laminar Flow Hood (LF (b)(4)) and Laminar Flow Hood (LFH (b)(4)) from studies completed in August 2025 and February 2026. The following deficiencies were observed: i. Incomplete Coverage of Critical Production Steps. Across both August 2025 and February 2026 AFV studies, the dynamic airflow visualization did not encompass all critical steps performed during commercial production operations. For example, the following steps were not captured in either study period: Drawing drug product from vials into a (b)(4) mL syringe using (b)(4) needle, syringe preparation, cap preparation, opening of syringe and cap boxes (trays of units), picking up and attaching caps to filled syringes, and the capping process. Only the filling of each (b)(4) mL syringe to the 0.07 mL mark was consistently captured. This deficiency was observed across multiple video records. ii. Stationary Fogger Wand and Absence of Airflow Visualization Over Critical Work Zones. In multiple video records from February 2026, the fogger wand was held stationary rather than maneuvered to cover all critical work surfaces and product-contact areas. For example: In the provided video (LFH (b)(4) Repacking, dynamic), no airflow visualization was observed over the syringe to be filled or cap containers from T=(b)(4) to T=(b)(4), and no AFV was observed over the filling area at T=(b)(4). In the provided video (LF Sterile (b)(4), dynamic), the fogger wand was stationary, and no airflow visualization was captured over the initial collection of drug product from the (b)(4) container into the syringe (T=(b)(4) to T=(b)(4)). In the provided video (LFH Repacking, dynamic), the fogger wand remained stationary throughout the entire video, with no airflow visualization captured over the syringe and cap containers at any point during the study. iii. Absence of AFV During Dynamic (Operational) Conditions. In the provided video (LFH (b)(4)) (February 2026), airflow visualization was observed only under static conditions (T=(b)(4) to T=(b)(4)). Once the operator began preparation for production, no AFV was conducted during the dynamic phase (T=(b)(4) to T=(b)(4)), despite dynamic studies being required to reflect actual operational conditions. iv. Absence of Active Air Sampling During AFV Studies. In all three August 2025 video records covering both LFH (b)(4) and LFH (b)(4), no active air sampling was performed concurrent with the AFV studies. Active air sampling during AFV studies is necessary to assess and document the microbiological quality of the environment under simulated or actual operational conditions. The AFV studies for ISO 5 LFH (b)(4) and LFH (b)(4) conducted in both August 2025 and February 2026 were incomplete and did not adequately simulate or represent actual commercial production operations, including critical manual steps and interventions. These deficiencies indicate that unidirectional airflow protection over open product and product-contact components during critical production steps have not been adequately characterized or verified, which poses a risk to sterility assurance and the quality of the drug product. C. Media fills were not representative of routine production. Review of the media fills revealed the following discrepancies: i. Your firm's two most recent media fill runs were conducted, spanning from (b)(4) to (b)(4), with personnel rotation across all (b)(4) employees over a period of up to (b)(4) days. Review of the records revealed that on media fill run days, your firm simultaneously conducted commercial production lots, producing up to (b)(4) lots per day across LFH (b)(4) and LFH (b)(4), operating across (b)(4) shifts and (b)(4) for a total of (b)(4) shifts per day. The media fill runs did not represent the worst-case production scenario, as they failed to account for all shift changes and the associated line clearances performed between production runs. For example, during both of the past two media fill runs, (b)(4) covered per media fill run, thereby not simulating all (b)(4) shifts or the corresponding line clearances and shift transitions that occur during commercial operations. ii. Review of the past two media fill batch records revealed that the records contained no directions specifying the required number of air samples an operator must collect or the prescribed time intervals at which sampling must occur. Consequently, all media fill batch records reviewed contained (b)(4), and none of the records included lot numbers for the associated media plates used during the runs. This is in contrast to commercial production, during which active air samples are taken per (b)(4). Your firm's media fill program does not adequately simulate worst-case aseptic processing conditions, as it fails to incorporate all shift changes, associated line clearances, and representative environmental monitoring practices observed during commercial production. This deficiency, compounded by unresolved sterility failures and incomplete investigation findings, raises significant concerns regarding your firm's ability to assure the sterility of its aseptically re-packaged drug product. D. The following inadequate aseptic technique behaviors were observed: Your procedure, SOP 65, Maintaining Sterile Environment, effective 04/08/2026, is deficient. For example, per this procedure, your sterile gloving and gowning must be performed entering the ISO 8 anteroom, which should be designated solely for pre-gowning activities, including the donning of head covers, masks, and shoe covers. However, it was observed that operators enter the ISO 8 anteroom directly from the labeling room wearing street garments and initiate aseptic gowning within the ISO 8 area itself. No physical or spatial separation exists within the ISO 8 room to support or delineate a gowning zone. ii. Prior to initiating production, operators in sterile gowning exited the ISO 7 cleanroom and entered the ISO 8 anteroom to collect media plates and components, then re-entered the ISO 7 area to begin production at the ISO 5 LFH, thereby exposing sterile gowning, including head covers and goggles, to a less-controlled environment before aseptic operations commenced. iii. During filling operations, after completing approximately the first half of the finished batch of filled syringes of Avastin in the ISO 5 LFH, operators exited the cleanroom and entered the ISO 8 anteroom carrying the filled syringes, placing them on the ISO 8 surface. Operators then collected additional drug vials, re-entered the ISO 7 cleanroom, and completed the remaining half of the lot. Upon re-entry to the ISO 5 LFH, operators changed only their sterile gloves and sleeve covers, without performing a full gown change following exposure to the ISO 8 anteroom environment. Additionally, during syringe filling, operators were observed leaning into the ISO 5 LFH such that their head covers and goggles extended into the ISO 5 work zone. Given that operators exited and re-entered the cleanroom multiple times during aseptic filling - exposing their sterile gowning to less-controlled environments - re-engaging in ISO 5 LFH operations constitutes a repeated and unmitigated breach of aseptic technique. E. Your Firm's environmental monitoring (EM) program for the cleanroom area is deficient. Per SOP 57, Testing of Sterile Environment, effective date 04/09/2026, operators are required to perform personnel sampling of fingertips and gown sleeves (b)(4). However, personnel sampling of the sterile head/face covers and face goggles is not included in the sampling protocol. As described in the previous Observation 1D, operators exit and re-enter the ISO 7 cleanroom through the ISO 8 anteroom multiple times during the filling/repackaging operation and place their head/face coverings and goggles into the ISO 5 critical area during the filling process. The absence of head/face cover and goggle sampling therefore leaves a significant gap in personnel contamination monitoring. ii. Personnel sampling for fingertips and gown sleeves is performed only (b)(4), not after completing the first half. The firm's current sampling practice, therefore, does not adequately represent the full fingertip and gown sleeve contamination exposure throughout the filling/repackaging cycle, as the first half of the lot is completed prior to the ISO 8 anteroom exit and is not captured by (b)(4) sampling. iii. Your firm does not perform surface sampling in the ISO 8 anteroom on a routine basis; samples collected every (b)(4) as part of the ISO room qualification program. Additionally, while your firm conducts (b)(4) active air sampling, the selected sampling frequencies and locations are not supported by a documented risk assessment based on your historical environmental data. iv. Your firm monitors non-viable particulates (NVP) in the ISO 5 laminar flow hood (LFH), ISO 7, and ISO 8 classified areas using (b)(4) NVP equipment (Manufacturer: (b)(4), Model (b)(4)) in each classified space. Active air samplers (SAS) are also (b)(4) in LFH (b)(4) and LFH (b)(4). The following deficiencies were noted regarding equipment location selection and orientation for both NVP and SAS equipment: LFH (b)(4) ((b)(4) wide) and LFH (b)(4) ((b)(4) wide) operate with (b)(4) airflow. The NVP (b)(4) sample (b)(4) and SAS units in both LFHs are positioned (b)(4) to the LFH airflow and are located near the end corners of the respective hoods, rather than in close proximity to the filling/repackaging station, with no scientific justification. Likewise, the SAS orientation and placement in both LFHs have not been justified. The NVP (b)(4) sample (b)(4) in LFH (b)(4) is located near the (b)(4) end corner, approximately 2-2.5 feet from the filling/repackaging station. Particulate monitor placement must be representative of and in close proximity to the active filling/repackaging process to yield meaningful monitoring data. (b)(4) installed in each of the ISO 7 and ISO 8 rooms. The location selection rationale for these instruments was based primarily on practical considerations - such as proximity to a (b)(4) connection - rather than on a risk assessment derived from historical environmental data. Your firm's environmental monitoring program contains multiple significant deficiencies in personnel sampling coverage, surface and air sampling frequency, and the placement and orientation of particulate monitoring and active air sampling equipment. None of these practices are supported by documented risk assessments. Collectively, these deficiencies compromise your firm's ability to detect and respond to potential microbial and particulate contamination during sterile filling/repackaging operations, posing a risk to product sterility assurance and patient safety.

为防止“声称无菌”的药品受微生物污染而设计的程序，未包含对无菌与灭菌工艺的充分验证。五块：

A. 烟雾研究只有视频，没有研究。2025 年 8 月与 2026 年 2 月，企业为两台 ISO 5 层流罩各做了一轮静态加动态的气流可视化（AFV）。两轮都没有任何正式研究报告或支持性文件；记录里缺烟雾源类型、研究目的、目标测试位置、动态条件下的人员活动、实时观察与结论。视频拍了，但没有书面方案、没有同期记录、没有能解释或佐证画面的总结报告——视频成了“拍过就算”的孤证。

B. 视频本身也问题成堆。其一，关键步骤没拍：从西林瓶抽药到 (b)(4) ml 注射器、注射器准备、瓶盖准备、开盒、取盖装到灌好的注射器上、拧盖——两轮研究都没拍到，唯一每次都拍到的只有“灌到 0.07mL 刻度”这一个动作。其二，发烟棒固定不动：2026 年 2 月多个视频里，发烟棒被杵在一个位置，没有移动着覆盖关键工作面，待灌注射器和瓶盖容器上方始终没有气流画面。其三，动态阶段干脆没做：2026 年 2 月一段视频只在静态条件下（T=(b)(4) 至 T=(b)(4)）拍了气流，操作员一开始做生产准备，动态阶段（T=(b)(4) 至 T=(b)(4)）就没有了——而动态研究存在的意义正是反映实际运行条件。其四，全程没有同步主动空气采样：2025 年 8 月三段视频里一次都没有，而同步采样正是评估“运行条件下环境微生物质量”的必要手段。FDA 的结论是：关键步骤中，开放产品与产品接触组件上方的单向流保护从未被充分表征或验证。

C. 培养基灌装不代表实际生产。最近两次介质填充横跨 (b)(4) 至 (b)(4)，全员 (b)(4) 人轮换、最长 (b)(4) 天；但记录显示，做介质填充的当天企业同时在跑商业生产批——两台层流罩每天最多 (b)(4) 个批，跨 (b)(4) 个班次。介质填充既没有覆盖全部换班，也没有模拟班次之间的清线，因此不构成最差场景。另外，两次介质填充的批记录里根本没有“操作员必须采集多少空气样品、按什么时间间隔采样”的指令，也没有当次所用培养基平皿的批号——而商业生产中是要按 (b)(4) 采主动空气样的。FDA 把这条与“未解决的无菌失败、不完整的调查”并列，认为它直接动摇了企业保证其无菌再分装产品无菌性的能力。

D. 无菌行为反复破防。规程 SOP 65《维持无菌环境》（2026/4/8 生效）本身就有缺陷：按它自己的规定，无菌戴手套与更衣应在进入 ISO 8 前室时完成，前室只用于戴头套、口罩、鞋套等预更衣——但现场看到操作员穿着便服直接从标签间走进 ISO 8 前室，就在那里开始无菌更衣，房间内没有任何物理或空间分隔来界定更衣区。开产前，已穿好无菌服的操作员还要退出 ISO 7、进 ISO 8 去取培养基平皿和组件，再回 ISO 7 上 ISO 5 操作——无菌服（含头套、护目镜）在无菌操作开始前就暴露在了等级更低的环境里。灌装 Avastin 时更直接：灌完大约前半批，操作员拎着灌好的注射器退出洁净间、走进 ISO 8、把它们放在 ISO 8 台面上，取来更多药瓶后回 ISO 7 灌完后半批；回到 ISO 5 时只换了手套和袖套，没有做全身更衣。此外还有人俯身进入层流罩，头套和护目镜都伸进了 ISO 5 作业区。FDA 的定性是：反复进出、反复暴露，构成反复且未加任何缓解的无菌行为破防。

E. 环境监测四处漏风。按 SOP 57《无菌环境测试》（2026/4/9 生效），人员采样只做指尖和袖套——头套/面罩与护目镜不在采样范围，可操作员偏偏多次经 ISO 8 进出、并把头面护具伸进 ISO 5，这块空白很致命。指尖与袖套又只在 (b)(4) 做，批的前半段（恰在退出 ISO 8 之前完成）根本没被覆盖。ISO 8 前室不做常规表面采样，只在房间确认时每 (b)(4) 采一次。主动空气采样虽然做了，频次和点位却没有任何基于历史数据的风险评估。设备布置更随意：两台层流罩里的微粒探头和主动空气采样器都摆在罩子尽头角落、离灌装工位约 2–2.5 英尺，理由主要是“离 (b)(4) 接口近”这类实际便利，而不是风险评估。FDA 总结：这些做法没有任何一项有书面风险评估支持。

FDA 的真实关切：观察项 1 是一份"验证造假/失效的解剖图"——视频拍了却不写报告，写了报告的（Olympia 类似案例）也与画面矛盾；介质填充避开换班清线这个最差场景；现场的无菌行为破防一而再、再而三。每一层"证据"都经不起对账。法规：21 CFR 211.113(b)、211.111、211.42；USP <797>/<1116>。

观察项 2｜无菌失败调查不彻底：4 批被拒，同日同罩的 10 批照样放行

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. Specifically, Sterility test failure investigations for aseptically re-packaged Avastin 1.25 mg/0.05 mL were inadequate and failed to identify probable root causes. Since October 2025, the firm has rejected four batches due to sterility failures. Despite the rejection of these batches, other batches manufactured on the same day and in the same laminar flow hood in the table below were released without a scientifically sound justification or supporting data demonstrating adequate risk mitigation: (Fill date 10/17/2025: Rejected lot 120251017-01A42E; Released lots manufactured in the same hood 120251017-0FFESB, 120251017-235C2A; Released lots manufactured in the 2nd hood 120251017-6D87A5, 120251017-03F240). (10/21/2025: Rejected 120251021-01F7A1, 120251021-5C30B4; Released same hood 120251021-8CC0D9; Released 2nd hood 120251021-1BEBE6, 120251021-817D6D). (3/09/2026: Rejected 120260309-SFE1A0; Released same hood 120260309-141A33, 120260309-80AC52; Released 2nd hood 120260309-3645AC). (6/15/2026: Rejected 120260615-4D607D; Released same hood 120260615-812D57, 120260615-42D2D3; Released 2nd hood 120260615-7E9720). Your firm's failure to identify probable root causes for sterility test failures raises significant concerns regarding the robustness of the aseptic filling operations and the integrity of the contamination control strategy. The release of concurrent batches - manufactured under the same conditions as the rejected lots - without adequate scientific justification or documented risk mitigation poses a direct risk to patient safety, as those products may not meet sterility assurance requirements.

无论批次是否已分销，企业都未能彻底审查任何无法解释的差异与不合格。最重的一条是：无菌再分装 Avastin 1.25mg/0.05mL 的无菌检查失败调查不充分，从未确定可能的根因。自 2025 年 10 月以来，企业因无菌失败拒收了 4 个批次——但同一天、同一台层流罩生产的其他批次照常放行：

FDA 的评价很直白：查不出无菌失败的可能根因，本身就说明无菌灌装操作的稳健性和污染控制策略的完整性都成问题；而把与拒收批同条件生产的并行批次，在没有任何科学理由或成文风险缓解的情况下放行，对患者安全构成直接风险——这些产品可能根本不满足无菌保证要求。

FDA 的真实关切：4 次拒收 = 4 次未找到根因 = 同环境下的 10 个批次带着同样的未知风险进了市场。这条与眼内炎不良事件的关联最直接，也是警告信后监管升级的核心证据。法规：21 CFR 211.192。

互动 一支要打进眼睛的药，无菌失败调查不清、同批还放行——你觉得这该不该启动召回？

观察项 3｜人流物流共用一条道：换衣靠扶墙，门把手被消毒剂泡烂

Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations. Specifically, A. Personnel and material flow into and out of the ISO 7 and ISO 8 classified areas occurs through a single shared pathway that passes directly through the visual inspection and labeling room. Gowning, degowning, and material transfer - including finished product exiting the cleanroom and incoming components entering - all traverse the same corridor used for labeling and visual inspection of previously released product, creating a convergence of traffic that is inconsistent with unidirectional flow principles. Specifically, operators completing shoe covers, head covers, masks, and hand washing in the non-classified area must traverse this shared labeling room pathway to reach the ISO 8 entry door. Upon degowning, operators must similarly walk from ISO 7, through ISO 8, and through this same labeling room, where other staff are actively performing packaging, labeling, and visual inspection activities, to reach an outside corridor. No designated degowning area exists within the ISO 8 anteroom. Additionally, no physical or spatial separation exists within the ISO 8 anteroom to support or delineate a gowning zone, and operators were observed leaning against ISO 8 walls and tables for stability during gowning, introducing a potential source of contamination to sterile garments. B. Within this same access route, a door handle providing passage between the ISO 7 and ISO 8 classified areas and the labeling room was observed to be visibly degraded due to repeated exposure to cleaning and disinfecting agents. Furthermore, the curved geometry of the handle prevents adequate cleaning and disinfection of all contact surfaces. C. Airflow vents in the ISO 7 cleanroom and ISO 8 anteroom are obstructed. For example, multiple items - including storage containers, a table, and bottles - were observed blocking the air vents in the ISO 8 anteroom. The shared personnel and material pathway through the visual inspection and labeling room, the absence of a designated gowning and degowning zone, a deteriorating and inadequately cleanable door handle, and obstructed airflow vents collectively represent significant deficiencies in contamination control infrastructure. These conditions compromise the environmental integrity of the ISO 7 and ISO 8 classified areas and present a risk of cross-contamination to finished product, released materials, and ongoing sterile production operations.

为防止污染或混淆而设的隔离与限定区域，在生产和加工操作上失守：

A. 人流物流共用一条道。人员与物料进出 ISO 7/ISO 8 走的是同一条通道，而且这条通道直接穿过灯检与标签间。更衣、脱衣、物料转运（成品出洁净间、来料进洁净间）都要走这条走廊，而那里正有其他员工在对已放行产品做包装、贴标和灯检——人流物流在此汇聚，完全违背单向流原则。ISO 8 前室里既没有指定的脱衣区，也没有任何物理或空间分隔来界定更衣区；检查员还看到操作员更衣时靠在 ISO 8 的墙和桌子上借力，无菌服由此多了一个污染源。

B. 门把手被消毒剂泡烂了。这条通道上，ISO 7/ISO 8 与标签间之间的门把手因反复接触清洁消毒剂已肉眼可见地劣化；而它的弧形结构又使所有接触面都无法被充分清洁消毒。

C. 回风口被堵。ISO 7 洁净间与 ISO 8 前室的通风口被储物容器、一张桌子和若干瓶子挡住。

三者合起来，FDA 的定性是：污染控制基础设施存在重大缺陷，危及 ISO 7/ISO 8 的环境完整性，给成品、已放行物料和正在进行的无菌生产带来交叉污染风险。

FDA 的真实关切：洁净区的"区划"从图纸阶段就没做对：更衣无分区、人流物流一条道、风口堆杂物——这是把无菌生产的硬件底座整体装反了。法规：21 CFR 211.42、211.56。

观察项 4｜清洁程序：ISO 7 日常不清扫，两次深度清洁之间隔了 49 天

There is a lack of written procedures assigning responsibility, providing cleaning schedules and describing in sufficient detail the methods, equipment and materials to be used for sanitation. Specifically, A. Your firm's cleaning procedure is inadequate. i. Your firm stated that only the ISO 5 laminar flow hood receives cleaning (b)(4). However, your firm failed to clean the ISO 7 classified area (b)(4), leaving cleaning to the end of production for the day. ii. Your firm lacks scientifically established and data-supported cleaning intervals for the cleanroom. A review of cleaning records revealed a 49-day gap between the (b)(4) deep cleaning performed on 02/09/2026 and the subsequent cleaning on 03/30/2026. Furthermore, your firm acknowledged that scheduling cleaning on a (b)(4) basis - rather than at fixed intervals - could permit up to (b)(4) between cleaning events. Cleaning intervals of this duration, without scientific justification or validated hold-time data, present an unacceptable risk of microbial proliferation and environmental contamination in a classified cleanroom, potentially compromising the sterility and quality of drug products manufactured therein.

清洁责任、清洁日程、清洁所用的方法/设备/材料，都没有写清楚。实际执行更糟：企业自述只有 ISO 5 层流罩接受 (b)(4) 清洁，ISO 7 区域不清——清洁被攒到当天生产结束才做。洁净间也没有任何经科学建立、有数据支持的清洁间隔：清洁记录显示，2026/2/9 那次 (b)(4) 深度清洁与下一次 3/30 的清洁之间隔了 49 天；企业自己还承认，按 (b)(4) 安排清洁（而非固定间隔），两次之间最长可能相隔 (b)(4)。这么长的间隔，在没有科学依据或经过验证的保持时间数据的前提下，等于给微生物滋生留足了时间。

FDA 的真实关切：清洁不是"有做就好"——间隔要科学、执行要按期、记录要可查。49 天不清扫的洁净间，环境监测数据再干净也难以自证。法规：21 CFR 211.56。

观察项 5｜温度分布确认：培养箱/冰箱只做过空载，装满货从来测过

Routine calibration, inspection and checking of automatic, mechanical and electronic equipment is not performed according to a written program designed to assure proper performance. Specifically, Your firm has not performed temperature mapping under the worst-case conditions for your critical equipment during equipment qualification. For example, your firm operates (b)(4) incubators (b)(4) and (b)(4) refrigerators (b)(4), all of which are used for product storage and environmental monitoring (EM) sample incubation. A review of the initial qualification records for these units revealed that temperature mapping was performed exclusively under empty-state conditions. When asked whether temperature mapping under operationally loaded conditions had been performed to reflect the units' current operational use, your firm confirmed that only the initial empty-state mapping had been completed and no subsequent studies have been initiated.

自动化、机械与电子设备的校准、检查与核对，没有按确保正确运行的书面程序执行。企业运行 (b)(4) 台培养箱和 (b)(4) 台冰箱，全部用于产品贮存与环境监测样品培养。审核初次确认记录发现：温度分布只在空载状态下做过。被问到是否做过装载运行状态下的分布（以反映设备当前实际用途），企业确认只做过最初的空载分布，此后再未启动任何后续研究——装满样品和空箱子，热分布完全是两回事，等于最差条件从未被验证过。

FDA 的真实关切：装满样品和空箱的热分布完全是两回事——确认只做空载，等于最差条件从未被验证过。法规：21 CFR 211.68（设备校验与确认）。

观察项 6｜微粒标准没有科学依据【2024 年 11 月 4 日 483 的重复项】

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity. Specifically, Your firm continues to fail to provide a scientific rationale to support the established method and limits for subvisible particle testing of Avastin (bevacizumab) 1.75 mg/0.07 mL for intravitreal injection. Your firm releases this product using a subvisible particulate matter specification of (b)(4) particles/container at (b)(4) µm and (b)(4) particles/container at (b)(4) µm. All (b)(4) lots associated with endophthalmitis adverse events were released using this particulate matter specification. This observation is a repeat observation from the previous FDA 483, List of Observations, issued on 11/04/2024.

实验室控制没有建立科学可靠、恰当的质量标准来保证药品符合鉴别、规格、质量与纯度要求。具体到这一条：企业至今仍拿不出科学依据，来支撑它对 Avastin（贝伐珠单抗）1.75mg/0.07mL 玻璃体内注射液所采用的亚可见微粒检测方法与限度。企业目前以“(b)(4) µm 每容器 (b)(4) 粒、(b)(4) µm 每容器 (b)(4) 粒”的标准放行该产品——而所有 (b)(4) 个与眼内炎不良事件相关的批次，都是用这个标准放行的。本条是 2024 年 11 月 4 日那份 483 观察项清单的重复项。

FDA 的真实关切：这是全篇最冷的一条——"continues to fail"（至今仍在失败）+ "repeat"（重复项）+ "与眼内炎不良事件相关的批次均由此标准放行"三重叠加：一个从未验证过的微粒标准，被用来放行了一批批打进患者眼里的药。法规：21 CFR 211.160(b)；USP <788>（注射剂不溶性微粒）。

观察项 7｜员工培训缺失：CGMP 培训根本不做

Employees are not given training in the particular operations they perform as part of their function, current good manufacturing practices and written procedures required by current good manufacturing practice regulations. Specifically, A. Your firm does not conduct periodic CGMP training for employees. B. Not all personnel receive basic training on the theory and practice of the Quality Management System and Good Manufacturing Practices, as required, per SOP-6 Training and Personnel, v2.0, effective September 30, 2025, Section 5.2.1. C. Your firm has not established training or qualification requirements to ensure that personnel responsible for reading and interpreting EM plate results are able to accurately enumerate and differentiate microbial growth and surface colonization.

员工没有接受与其岗位操作、现行 GMP、以及 GMP 法规所要求书面程序相关的培训：企业根本不开展定期 CGMP 培训；也不是所有人员都按自家 SOP-6《培训与人员》v2.0（2025/9/30 生效）第 5.2.1 节的要求，接受过质量管理体系与 GMP 理论与实践的基础培训；此外，企业没有建立任何培训或资质要求，来确保负责读取和判读环境监测平皿结果的人员，能够准确计数并区分微生物生长与表面定植。

FDA 的真实关切：连"多久培训一次"都答不上来的企业，前面 1–6 条的无菌行为破防、调查敷衍就有了人因解释。法规：21 CFR 211.25。

观察项 8｜标签不写储存温度，BUD 也没有稳定性数据支撑

Drug product expiration dates are not related to the storage conditions stated on the labeling, as determined by stability studies. Specifically, Your firm's product labels do not specify required storage temperature conditions, and the assigned (b)(4) beyond-use date (BUD) is not supported by stability testing. For example: your firm has failed to specify required storage temperature conditions on product labels, despite assigning a (b)(4) beyond-use date (BUD). For example, your firm stated that stability testing is not conducted for its non-sterile compounded products on the basis that the water activity content is less than (b)(4)%, with a (b)(4)-day BUD assigned at a controlled room temperature of (b)(4). However, all three non-sterile product labels reviewed during the inspection indicated only "room temperature," without further qualification or specification of the required temperature range, which is inconsistent with your firm's stated storage conditions.

药品有效期与标签标示的储存条件（由稳定性研究确定）对不上：产品标签不写要求的储存温度，所定的 (b)(4) 使用期（BUD）也没有稳定性试验支撑。企业给非无菌配制产品定 (b)(4) 天 BUD 的理由是“水分活度低于 (b)(4)%，在受控室温 (b)(4) 下储存”；但检查中审核的三个非无菌产品标签上只写了“室温”两个字，没有任何温度范围的限定或说明——与企业自称的储存条件不一致。BUD 的前提是“按标示条件储存”，标签不写温度，患者和药房无从照做，效期承诺也就失去了前提。

FDA 的真实关切：BUD 的前提是"在标示条件下储存"；标签不写温度，患者和药房就无从按条件储存，效期承诺失去了前提。法规：21 CFR 211.137。

三、主线收敛

8 条的主线比字数更清楚："证明体系有效的每一个动作，都没有真正做完。"烟雾研究拍了视频没有报告（1A–B），介质填充避开换班清线（1C），EM 采样点设在角落、理由是"离接口近"（1E），无菌失败查不出根因、同条件批次照放（2），洁净间隔了 49 天才清扫（4），温度分布只做空载（5），微粒标准两年没依据（6），培训不做（7），标签不写温度（8）。这不是某一台设备的故障，是一套体系从头到尾没有学会"用证据说话"。

四、严重度一览（节选高危项）

五、把这份 483 放回执法链条上看

RC Outsourcing 是本批 5 家企业里唯一一个已经在链条深处的：483（2024-09）→ 483（2024-11）→ 483（2025-08）→ 警告信 WL #722877（2026-03-20）+ 4 批召回 → 2026 年再检再中 8 条。警告信发出半年后检查，FDA 看的已经不是"有没有问题"，而是"警告信之后改了没有"——观察项 6 里那句"continues to fail"和"repeat observation from 11/04/2024"，就是对这个问题最直接的回答。这条链条上真正值得行业警觉的是观察项 6 那句话的另一种读法：所有与眼内炎不良事件相关的批次，都是用一个从未验证过的微粒标准放行的——监管数据、患者伤害、缺陷标准，在同一个句子里闭环了。对一家 503B 而言，这几乎就是执法升级路径上能拿到的最重的一块拼图。

当然，Form 483 本身不是最终判定。企业仍有回复与申诉的程序空间，FDA 也尚未公布本次检查的分类结论——以上是风险方向，不是判决书。

互动 四份 483、一封警告信、四批召回之后，一家企业还有多少次"整改"的机会？

声明：本文基于美国 FDA 公开的执法文书（Form 483 / Warning Letter / Import Alert 等）撰写，仅供医药行业质量管理与合规学习交流之用，不构成对任何企业的法律或商业评价。原始文书以 FDA 官网公布版本为准；文书内容不构成 FDA 的最终判定。